XML 60 R54.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting - Summary of Significant Expense Categories and Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]        
Revenue $ 11,790 $ 24,124 [1] $ 33,425 $ 69,252 [1]
Operating costs and expenses:        
Cost of goods sold 0 4,435 [1] 0 22,709 [1]
Clinical development, contract manufacturing and other third party costs 15,850 24,321 52,871 59,077
Employee costs 10,888 9,544 33,782 29,915
Facilities costs 3,052 3,779 9,378 12,417
Other operating costs 10,297 11,013 37,881 33,442
Other segment expenses 3,375 5,377 11,950 31,238
Total operating costs and expenses 43,462 58,469 [1] 145,862 188,798 [1]
Loss from operations (31,672) (34,345) [1] (112,437) (119,546) [1]
Non-operating income (expense):        
Non-cash interest expense on liabilities related to the sales of future royalties (6,047) (6,020) [1] (16,415) (17,959) [1]
Interest income 2,819 3,437 [1] 7,662 11,558 [1]
Other income (expense), net (121) (120) [1] 405 (255) [1]
Total non-operating income (expense), net (3,349) (2,703) [1] (8,348) (6,656) [1]
Loss before provision (benefit) for income taxes and equity method investment (35,021) (37,048) [1] (120,785) (126,202) [1]
Provision (benefit) for income taxes (33) 9 [1] (169) 20 [1]
Loss before equity method investment (34,988) (37,057) [1] (120,616) (126,222) [1]
Loss from equity method investment (534) 0 [1] (7,381) 0 [1]
Net loss (35,522) (37,057) [1] (127,997) (126,222) [1]
Rezpegaldesleukin (cytokine Treg stimulant)        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs 11,155 15,684 37,888 36,667
NKTR-255 (IL-15 receptor agonist)        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs 1,413 5,108 5,034 12,790
NKTR-0165 (tumor necrosis factor receptor type II agonist)        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs 3,119 3,900 8,931 7,751
Discovery Research and Other Programs        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs $ 163 $ (371) $ 1,018 $ 1,869
[1] All share and per share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 6).